Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the ...

The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

Aave (AAVE) sank toward $130, while four whales unstaked their positions from the Aave vaults and sent the tokens to ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...

Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12.50 per share in cash. The per share purchase price represents a ...

We are bullish on Avid's potential take-private deal by Ampersand and GHO, predicting value creation and optimistic about ...

GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices, a biologics contract development and manufacturing organization, in an all-cash transaction valued at ...

Believes Proposed Offer of $12.50 / Share Significantly Undervalues the Company and Does Not Adequately Compensate Shareholders for Exceptional Growth Ahead Does Not Intend to Vote For the Deal and ...

Avid Bioservices (NASDAQ:CDMO) has agreed to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at around $1.1B.

Avid Bioservices shares were up 12% at $12.25 after getting a buyout offer from GHO Capital Partners and Ampersand Capital Partners. Under the terms of the buyout, Avid will be acquired by funds ...

Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12.50 per share in cash. The per share purchase price ...